Objective: Vonoprazan is a new medication that helps treat Helicobacter pylori infections effectively. This study compares a 14-day treatment with vonoprazan and amoxicillin against personalized therapy based on drug sensitivity.
Methods: In this study, 240 adults who did not respond to previous H. pylori treatments were randomly assigned to either the vonoprazan-amoxicillin treatment or the personalized therapy. The main goal was to see how well each treatment worked, while also looking at side effects, patient adherence, and antibiotic resistance.
Results: Both treatments showed similar effectiveness in eradicating the infection, with success rates of 87.50% for vonoprazan-amoxicillin and 83.33% for personalized therapy. The vonoprazan-amoxicillin treatment had fewer side effects, and both groups had good patient adherence. Previous use of clarithromycin was linked to higher resistance rates.
Conclusion: The 14-day vonoprazan-amoxicillin treatment is effective and safe for patients needing retreatment for H. pylori infection.
Opportunities:
- Measurable Outcomes: Set clear treatment goals to track success in clinics and for patients.
- AI Tools: Choose AI solutions that fit specific clinical needs for better treatment management.
- Implementation: Start with a pilot project to track results, using AI tools to enhance treatment based on the study findings.
For AI solutions in medical management, contact us:
